Treatment management of hormone refractory prostate cancer remains a significant challenge to clinicians. Several managements about this incurable but treatable disease are planned, but no consensus has been reached on the treatment schedule. In the current study, the authors examined the effect of docetaxel, estramustine phosphate and carboplatin in patients with hormone refractory prostate cancer. They found that combination therapy with docetaxel, estramustine phosphate and carboplatin has significant clinical activity with acceptable toxicity profile in hormone refractory prostate cancer patients.